Randomly clinical study of ITP and NP regimens in the treatment of non-small cell lung cancer / 中国肺癌杂志

ABSTRACT

<p><b>BACKGROUND</b>To evaluate the efficacy and toxicity of ITP (ifosfamide + perarubicin + cisplatin) and NP (vinorelbine + cisplatin) regimens in the treatment of advanced non small cell lung cancer (NSCLC).</p><p><b>METHODS</b>One hundred inoperatable or recurrent patients with stage III and IV NSCLC were randomized into ITP group and NP group treated by the two regimens responsively for 2 or 3 cycles.</p><p><b>RESULTS</b>The overall response rate was 51.5% for ITP group and 50.9% for the NP group, respectively. There was no statistically significant difference of the overall response rate between the two groups ( P > 0.05). The major side effects were leukopenia and gastrointestinal reaction. The leukopenia incidence was higher in ITP group than that in NC group ( P < 0.05).</p><p><b>CONCLUSIONS</b>Both ITP and NP regimens are effective for the advanced NSCLC. Compared with ITP regimen, NP regimen has less bone marrow toxicity than ITP regimen.</p>